Alvogen And Natco Facing Decade Wait On Ibrutinib After US Appeal Fails
Delaware District Court Had Previously Rejected Four Patent Challenges
Executive Summary
The US Court of Appeals rejected all arguments brought by Alvogen and Natco in their appeal against an unfavorable lower court Imbruvica (ibrutinib) ruling, leaving the ANDA sponsors facing a significant wait to potential approval and launch.